ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,424.20
0.05%
Dow Jones
39,806.77
-0.49%
Gold vs US Dollar
2,416.015
-0.43%
Brent Oil
83.10
-0.51%
Bitcoin
71,306.92
-0.20%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) News

Entera Bio (ENTX)

Entera Bio Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ENTX
DateTimeSourceHeadlineSymbolCompany
15/05/202413:00GlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberNASDAQ:ENTXEntera Bio Ltd
13/05/202412:00GlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
10/05/202421:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTXEntera Bio Ltd
10/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
10/05/202421:10GlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
08/04/202413:30GlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
26/03/202412:30GlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
20/03/202412:00GlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
08/03/202421:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
08/03/202421:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
08/03/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
08/03/202421:05GlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
04/03/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
04/03/202413:30GlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
15/02/202422:10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
15/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
14/02/202411:05Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
02/02/202421:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
02/02/202421:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
30/01/202413:30GlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
16/01/202413:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
11/01/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202423:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202421:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
03/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
02/01/202422:19Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ENTXEntera Bio Ltd
27/12/202313:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
26/12/202313:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
 Showing the most relevant articles for your search:NASDAQ:ENTX

Your Recent History

HUOB
KANETH
BITKAN
COIN
BUENGBP
Buenos
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved